2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Klempner provides insight into unmet needs in NRG1 fusion–positive solid tumors, the novelty of seribantumab, and the potential clinical implications of the ongoing CRESTONE study.
Welcome to OncLive On Air™! I’m your host today, Jessica Hergert.
OncLive On Air™ is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by Elevation Oncology, we had the pleasure of speaking with Sam Klempner, MD, a medical oncologist at Massachusetts General Hospital, to discuss the potential utility of seribantumab in the treatment of NRG1 fusion–positive solid tumors.
Seribantumab blocks HER3 signaling and its downstream effects, making the agent an ideal treatment for patients with NRG1 fusions, which are driven by HER3 overactivation and confer a poor prognosis.
The novel monoclonal antibody is under study in patients with the rare fusion in the ongoing phase 2 CRESTONE study. The study has a planned enrollment of approximately 75 patients with recurrent, locally advanced, or metastatic solid tumors that have progressed or have been unresponsive to available therapies. The 15 tumor types that will be represented in the trial include cancers of the pancreas, lung, head and neck, breast, kidney, bladder, gallbladder, bile duct, and prostate; colorectal, ovarian, esophageal, and uterine cancers; and sarcomas and cholangiocarcinoma.
In our exclusive interview, Klempner provided insight into the unmet needs in NRG1 fusion–positive solid tumors, the novelty of seribantumab, and the potential clinical implications of the ongoing CRESTONE study.